A drug that works at the lower dose but not the higher one is not the cleanest story to tell the FDA. Bristol Myers Squibb found that out Monday, October 12, 2026, when admilparant, the LPA1 antagonist it is counting on to replace revenue lost to patent expirations, produced a split verdict in its pivotal ALOFT-IPF trial.
The study met its primary endpoint at the 60mg dose, with patients demonstrating a statistically significant benefit in absolute change in forced vital capacity from baseline to Week 52 compared with placebo. That matters: FVC is the amount of air you can force from your lungs, and slowing its decline is the clearest measurable signal a drug is doing anything in idiopathic pulmonary fibrosis.
At the 120mg dose, the company said the primary endpoint was not met. Investors were left to infer that while the 120mg arm may have shown a numerical effect versus placebo, it did not clear the trial’s statistical bar. Analysts called the high-dose miss confusing and in need of a better explanation.
That word, confounding, is doing a lot of work. In most clinical pharmacology, a higher dose produces a stronger effect. When it doesn’t, physicians and regulators begin asking questions about absorption, about exposure variability, about whether the dose-response curve is doing something unexpected. The mixed dosage results introduce uncertainty about the drug’s competitive edge, because the higher dose was anticipated to help differentiate Bristol Myers’ offering in a crowded IPF market.
The Pipeline Math Still Works, Barely
Bristol Myers needs admilparant badly. Its portfolio balances blockbuster and growth drugs such as Opdivo, Reblozyl, and Camzyos against patent expirations on older products like Revlimid and Eliquis. Analysts have projected admilparant sales in IPF could reach $1.3 billion by 2032, and the trial success adds to pipeline strength as Bristol Myers seeks to offset those expirations.
One analyst take captured the middle ground: the 60mg success could be enough to support a filing, but the lack of a clean dose response raises questions about the profile. A more optimistic camp argued the 60mg result is still likely to open a blockbuster opportunity, even if the narrative into regulators is messier than it needed to be.
The stock fell roughly 2.6% on the day, an instructive response. Markets opened higher, absorbed the nuance, and sold. The result carried added significance because reports in late September and early October pointed to liver-related safety events in the broader program, including one patient death tied to a case of multiorgan failure in a patient with other medical complications. Bristol Myers said admilparant demonstrated a well-tolerated safety profile across both doses, with discontinuations due to adverse events low and similar to placebo, providing at least partial relief on that front.
What the Dose Split Means for the Broader LPA1 Class
Bristol Myers is not the only company whose fortunes turned on this readout. Contineum Therapeutics shares jumped in pre-market trading Monday, then reversed and fell sharply, as investors processed what the mixed result means for Contineum’s own LPA1 antagonist, PIPE-791, which targets the same pathway.
While the 60mg Phase 3 success represents a large-scale confirmation that the LPA1 mechanism can work in IPF, the 120mg miss creates lingering questions about dose-response in the broader LPA1 drug class. The market disagreement, at least for a session, was a reminder that validation of a pathway is not the same thing as validation of a winner.
The competitive context makes the dosing question more urgent. Admilparant is entering a market that only recently saw its first new IPF approval in years: Boehringer Ingelheim’s nerandomilast, sold as Jascayd, won FDA approval for idiopathic pulmonary fibrosis on October 7, 2025, raising the bar for any newcomer to differentiate on efficacy and dosing. Earlier LPA1 drugs struggled in clinical testing; Bristol Myers discontinued BMS-986020 after hepatobiliary toxicity emerged, and other companies have shelved LPA1 programs after underwhelming efficacy.
What Investors Should Watch
The full dataset, expected at a future medical meeting, is the next real test. Investors need the actual FVC numbers at each dose arm, not just the topline success and failure, to understand whether 60mg and 120mg performed similarly in absolute terms or whether something more puzzling is happening pharmacologically. If the two arms are close in absolute effect and the difference is statistical noise, the regulatory path clears. If there is a genuine dose-response reversal, that is a harder conversation.
Bristol Myers also reported positive Phase 3 data the same day for RYZ101, its actinium-225 radiopharmaceutical, which met its primary endpoint with a statistically significant improvement in progression-free survival in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. That win, meanwhile, barely registered against admilparant’s dose-response puzzle. With a market cap of roughly $118 billion and Q3 earnings due October 29, management will face questions from both angles. The trial technically succeeded. The harder work is explaining what a blockbuster looks like when it only proved itself at one of two doses.
